Invion Ltd. · ASX:IVX

Invion — Shareholder Meeting (October 2020)

13 slides from Invion's shareholder meeting presentation, Oct 21, 2020

  1. Slide 1: Annual General Meeting 21 October 2020

    For personal use only ANNUAL GENERAL MEETING 21 OCTOBER 2020 ©Copyright Invion Limited| A C N 094 730 417| A S X : I V X

  2. Slide 2: Transforming Photodynamic Therapy for novel & effective treatments for cancer

    For personal use only Transforming Photodynamic Therapy for novel & effective treatments for cancer Annual General Meeting 2020

  3. Slide 3: Company Overview: Developing the Next-Gen PDT

    COMPANY OVERVIEW Developing the Next-Gen PDT For personal use only Developing PhotosoftTM technology and new IVX-PDT formulations to treat range of cancers (topical and intravenous use) New Active Pharmaceutical Ingredients (APIs) based on PhotosoftTM technology show greater activity in in-vitro tes

  4. Slide 4: COVID-19 Impact: Managing the disruption

    COVID-19 IMPACT Managing the disruption For personal use only Global crisis limiting work of medical research community, including Invion’s partner organisations. Second shutdown of Victoria had larger impact as most of Invion’s resources are based in the state. Invion deferred clinical trials (BCC

  5. Slide 5: Photodynamic Therapy: A Novel Cancer Treatment

    PHOTODYNAMIC THERAPY: A NOVEL CANCER TREATMENT For personal use only Photodynamic therapy (PDT) Combines photosensitiser Generates reactive oxygen Direct cell death and 1 compound with light- 2 species causing damage to 3 induction of inflammatory induced activation organic molecules response Light

  6. Slide 6: Advantages of Photosoft Technology

    ADVANTAGES OF PHOTOSOFT™ TECHNOLOGY For personal use only PDT is a proven, effective cancer Is inert without light and Absorbs light in wavelengths to “light therapy. Photosoft™ has been rapidly clears from cells up” a tumour (diagnostic) or improved since inception activate oxygen free radicals tha

  7. Slide 7: Photosoft Technology and IVX-PDT

    Photosoft™ Technology For personal use only • Chlorin- based photosensitiser, multiple excitation peaks NEXT • Blue light – strong red fluorescence for lesion visualisation GENERATION PDTS: • Red light – generation of ROS for directed tissue ablation PHOTOSOFT™ • Non-toxic and tolerated at high dose

  8. Slide 8: Milestones in FY20: Progress Towards Commercialisation

    MILESTONES IN FY20 PROGRESS TOWARDS COMMERCIALISATION For personal use only NEW APIs DISCOVERED •Discovery of new Active Pharmaceutical Ingredients (APIs) with greater anti-cancer activity than IVX-P02 and IVX-P03 NEW PARTNERSHIP •Secured research collaboration with Peter MacCallum Cancer Centre •Th

  9. Slide 9: Board and Management: Experienced Leadership

    BOARD AND MANAGEMENT EXPERIENCED LEADERSHIP For personal use only THIAN CHEW MELANIE LEYDIN EXECUTIVE CHAIRMAN / CEO (INCOMING) CFO AND COMPANY SECRETATRY • Managing Partner, Polar Ventures • Principal of chartered accounting firm, Leydin Freyer. • Executive Director, Goldman Sachs proprietary • Bac

  10. Slide 10: Discovery and Development: World Leading Experts and Scientific Advisors

    DISCOVERY AND DEVELOPMENT WORLD LEADING EXPERTS AND SCIENTIFIC ADVISORS For personal use only DR ANDREW STEPHENS ASSOC. PROFESSOR LOUIS IRVING CANCER BIOLOGY ADVISOR SCIENTIFIC ADVISOR – LUNG CANCER • 15+ years experience in novel treatment research • Lung Cancer; Respiratory Physician, Peter MacCal

  11. Slide 11: Pathway to Success into 2021

    PATHWAY TO SUCCESS For personal use only Into 2021 Stronger platform to prepare for clinical trials & new growth levers Expanding into new Improving IVX-PDT levers for growth Building on the team APIs to pursue Generating and value (e.g. Preparation for and partnerships addition promising pre- cosme

  12. Slide 12: Summary: Building Shareholder Value

    SUMMARY BUILDING SHAREHOLDER VALUE For personal use only Current development program is fully funded New APIs showing greater promise for PhotosoftTM technology Multiple cancer opportunities and near-term value creating milestones Additional growth avenue from cosmeceutical supply agreement

  13. Slide 13: For personal use only

    For personal use only

Invion — Shareholder Meeting (October 2020) on 6ix